Motzer R - Search Results

1

Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma.

Nadal R, Amin A, Geynisman DM, Voss MH, Weinstock M, Doyle J, Zhang Z, Viudez A, Plimack ER, McDermott DF, Motzer R, Rini B, Hammers HJ. Nadal R, et al. Among authors: motzer r. Ann Oncol. 2016 Jul;27(7):1304-11. doi: 10.1093/annonc/mdw160. Epub 2016 Apr 7. Ann Oncol. 2016. PMID: 27059553 Free PMC article.

2

Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression.

Motzer RJ, Nanus DM, O'Moore P, Scher HI, Bajorin DF, Reuter V, Tong WP, Iversen J, Louison C, Albino AP, et al. Motzer RJ, et al. Cancer Res. 1992 Oct 15;52(20):5775-9. Cancer Res. 1992. PMID: 1394202 Clinical Trial.

3

A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma.

Ilson DH, Motzer RJ, Kradin RL, Vogelzang NJ, Bajorin DF, Scher HI, Nanus D, O'Moore P, Marathias K, Bosl GJ. Ilson DH, et al. Among authors: motzer rj. J Clin Oncol. 1992 Jul;10(7):1124-30. doi: 10.1200/JCO.1992.10.7.1124. J Clin Oncol. 1992. PMID: 1607918 Clinical Trial.

4

Phase II trial of Didemnin B in patients with advanced renal cell carcinoma.

Motzer R, Scher H, Bajorin D, Sternberg C, Bosl GJ. Motzer R, et al. Invest New Drugs. 1990 Nov;8(4):391-2. doi: 10.1007/BF00198598. Invest New Drugs. 1990. PMID: 2084073 Clinical Trial.

5

Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients.

Mencel PJ, Motzer RJ, Mazumdar M, Vlamis V, Bajorin DF, Bosl GJ. Mencel PJ, et al. Among authors: motzer rj. J Clin Oncol. 1994 Jan;12(1):120-6. doi: 10.1200/JCO.1994.12.1.120. J Clin Oncol. 1994. PMID: 7505805

6

Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors.

Motzer RJ, Bajorin DF, Schwartz LH, Hutter HS, Bosl GJ, Scher HI, Lyn P, Fischer P. Motzer RJ, et al. J Clin Oncol. 1994 Nov;12(11):2277-83. doi: 10.1200/JCO.1994.12.11.2277. J Clin Oncol. 1994. PMID: 7525885 Clinical Trial.

7

Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro.

Motzer RJ, Schwartz L, Law TM, Murphy BA, Hoffman AD, Albino AP, Vlamis V, Nanus DM. Motzer RJ, et al. J Clin Oncol. 1995 Aug;13(8):1950-7. doi: 10.1200/JCO.1995.13.8.1950. J Clin Oncol. 1995. PMID: 7636535 Clinical Trial.

8

Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma.

Motzer RJ, Lyn P, Fischer P, Lianes P, Ngo RL, Cordon-Cardo C, O'Brien JP. Motzer RJ, et al. J Clin Oncol. 1995 Aug;13(8):1958-65. doi: 10.1200/JCO.1995.13.8.1958. J Clin Oncol. 1995. PMID: 7636536 Clinical Trial.

9

Phase II trial of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinoma.

Law TM, Mencel P, Motzer RJ. Law TM, et al. Among authors: motzer rj. Invest New Drugs. 1994;12(4):323-5. doi: 10.1007/BF00873048. Invest New Drugs. 1994. PMID: 7775134 Clinical Trial.

10

Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up.

Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE. Minasian LM, et al. Among authors: motzer rj. J Clin Oncol. 1993 Jul;11(7):1368-75. doi: 10.1200/JCO.1993.11.7.1368. J Clin Oncol. 1993. PMID: 8315435 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

631 results

Search Page

Filters